Latest news with #healthcare
Medical News Today
27 minutes ago
- Health
- Medical News Today
Cold weather and joint pain: What is the connection?
Effects Who it affects Managing pain Contacting a doctor FAQ Summary Cold weather may worsen joint pain in some people, such as those with arthritis or orthopedic implants. Keeping warm by dressing appropriately for the weather and using draft excluders at home may help. Many people with health conditions such as arthritis report worsening joint pain when temperatures drop. Some research supports this, but more studies may be necessary for scientists to understand exactly why this happens and how common it is. Taking steps to stay warm may help reduce joint pain during cold weather. However, if someone experiences severe or persistent pain that interferes with their daily life, it is a good idea to speak with a healthcare professional. CatherineHistorically, most evidence of a link between cold weather and joint pain was anecdotal. However, in recent years, more researchers are investigating a cause-and-effect link. A 2025 review suggests that low temperatures may affect: compliance of the periarticular structures, which are tissues around a joint viscosity (resistance to flow) of synovial fluid, which is in joint cavities the ability of substances to pass through blood vessels, which may affect inflammation blood vessel constriction These effects may lead to increased joint pain and stiffness during cold weather. A 2023 systematic review of 14 studies suggests a correlation between increased osteoarthritis joint pain and lower temperatures, as well as increased atmospheric pressure and relative humidity. A potential cause for this is an overexpression of thermosensitive transient receptor potential channels (thermo-TRPs) in cold weather. Thermo-TRPs are a type of protein structure in cells involved in functions such as body temperature regulation and pain perception. However, the researchers conclude that more research is necessary to fully understand the links between osteoarthritis pain and weather conditions, including temperature. According to the 2025 review, cold weather may affect how people use care resources for health conditions such as arthritis. For example, lower temperatures may make people less likely to use physical therapy, which could contribute to increases in their symptoms. The Arthritis Foundation also suggests that cold weather may contribute to lower moods, which may cause people to focus more on their pain. More research is necessary to understand exactly how cold weather affects joint pain and other factors that may contribute. Not everyone will experience joint pain when it gets colder. However, certain health conditions may increase a person's chance. Pain is subjective and varies from person to person, even among people with the same health conditions. Mild pain for one person may feel severe for another. So, there is no guarantee everyone with arthritis will have painful joints when it gets colder. A 2020 study also suggests a link between cold weather and increased pain in people with orthopedic implants, such as joint replacements. If someone tends to experience worsening joint pain in colder temperatures, it can help to monitor weather forecasts to anticipate weather changes before they happen and take steps to prepare. Keeping warm may help reduce joint pain due to cold weather. People can try the following steps: wear warm clothes, such as gloves and multiple layers choose clothes made from insulating materials, such as wool use hot water bottles or portable hand warmers use heat pads or heated blankets at home place draft excluders or door sweeps on doors at home eat a hot meal or drink a warm drink move around to boost circulation If someone has a health condition that affects their joints, sticking to their treatment plan even during cold weather can help prevent worsening joint pain. A person's symptoms may differ depending on factors such as underlying health conditions, current treatments, and more. If someone does not have a diagnosed health condition but starts experiencing persistent or frequent joint pain, a doctor can diagnose the underlying cause. People with a health condition, such as arthritis, may benefit from speaking with a healthcare professional if they experience a severe flare-up or worsening symptoms. Their healthcare team may wish to change their current treatment plan to help them manage their symptoms. Although warmer temperatures may improve joint pain for some people, other weather factors, such as humidity and barometric pressure, can also affect joint pain. Treatment compliance and other factors may also contribute. The Arthritis Foundation suggests there is no guarantee a warmer climate will help. However, people can visit a new climate at different times throughout the year before committing to moving to see if their symptoms improve. No scientific studies support an 'ideal' temperature to reduce joint pain. The most comfortable temperature to relieve joint pain may vary from person to person. People can use a symptom journal to help work out what temperatures seem to relieve their joint pain and what temperatures worsen it. No scientific research supports using copper or magnetic bracelets to relieve joint pain during cold weather. However, the Arthritis Foundation suggests there is no harm in trying this remedy alongside a doctor-approved treatment plan. Some people may find that their symptoms improve due to the placebo effect. Cold weather may trigger or worsen joint pain in certain people, such as those with arthritis or joint replacements. Low temperatures may affect the fluid and tissues in and around joints, causing pain and stiffness. People may also focus on symptoms more and be less likely to follow treatment plans in cold weather. Taking steps to keep warm may help relieve joint pain that worsens in cold weather. This may include wearing multiple layers, using hand warmers or heat pads, and fitting draft excluders at home. Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources to ensure content accuracy and integrity. You can learn more about how we ensure our content is accurate and current by reading our editorial policy.
News24
36 minutes ago
- Health
- News24
These are the children the United States left to die in Mozambique
In Mozambique, the health system is overwhelmingly built on US money. When the Trump administration instantly pulled much of this funding without warning, disease and death spread. Spotlight and GroundUp visited one of the worst affected regions to describe the human toll. Hospitals run short of life-saving drugs. Doctors and nurses are laid off en masse. Hospital lines get longer and longer. Some patients are given the wrong medication, likely because the data capturers (who manage patient files) have lost their jobs. Community case workers who deliver HIV medication to orphaned children stop coming. Without their antiretrovirals (ARVs), some of these children die, GroundUp reports. Following US President Donald Trump's executive order to suspend US global aid funding on 20 January, the health system in parts of Mozambique fell into a state of chaos. US aid agencies had financed much of the country's healthcare workforce, along with the transportation of drugs and diagnostic tests to government hospitals. In some provinces, this money came from the US Centres for Disease Control and Prevention (CDC), which restored much of its funding shortly after the executive order. But in the central provinces of Sofala and Manica the money came from the US Agency for International Development (USAID), which permanently pulled most of its grants. For a week in June, I travelled to nine rural villages and towns across the two provinces. Interviews with grieving caregivers, health workers and government officials across these settlements all converged on one clear and near-universal conclusion: the funding cuts have led to the deaths of children. One of the clearest reasons is this. After USAID-backed community health workers were dismissed, thousands of HIV-positive children under their care were abandoned. Panic at all levels In 2020, a Sofala-based organisation called ComuSanas received a large USAID grant to employ hundreds of community workers throughout rural parts of the province. 'The project aimed to reduce mortality among children living with HIV,' says Joaquim Issufo, a former community worker with the project. He spoke to me from a street market in the impoverished district of Buzi, where he now runs a stall selling fish. 'We worked with children aged 0 to 17, especially orphans and vulnerable children.' These children live in remote villages, far away from public amenities. Some were found living in homes without any adults. Many others live with an elderly grandparent who can barely afford to feed them. Jesse Copelyn/GroundUp In the midst of poverty and isolation, the case workers, known locally as activists, functioned as a bridge between these children and the country's hospitals. They shuttled diagnostic tests between communities and health facilities. They brought children their medicines and ensured they took the correct doses at the right times. And they accompanied them to health facilities, and helped them weave through bureaucracy. Issufo notes that their role also extended far beyond health: they organised birth certificates, enrolled children in schools and referred them for housing. When drought and famine ripped through villages, they brought food baskets and provided nutritional education. In the villages that I went to, children and their caregivers referred to the activists as 'mother', 'father' or 'sister', and said that they were like family members. But after USAID issued stop-work orders to ComuSanas in January, those 'mothers and fathers' abruptly stopped visiting, and suddenly the region's most desperate children were left to fend for themselves. Issufo says that after this, there was 'panic at all levels, both for us as activists and also for our beneficiaries'. Children hospitalised and left for dead About 80km from Issufo's fish stall is the village of Tica, in the Nhamatanda district. Amid homes of mud brick and thatch, a group of former ComuSanas activists sit on logs, buckets and reed mats and explain the consequences of the programme's termination. '[Before the USAID cuts], I was taking care of a boy because [he] lives with an elderly woman, and she had to work,' says Marta Jofulande, 'I had to go to the health facility and give the child his [ARV] medication. I also helped to do things like preparing food. But with this suspension, I couldn't go anymore.' Jesse Copelyn/GroundUp Shortly after, Jofulande was told by the child's elderly caregiver that he had fallen ill, and was in critical care at a central hospital. 'I was the one bringing the [ARVs] to him,' says Jofulande, 'As soon as the programme stopped, he no longer took the medication, and that's when he relapsed. He is in a very critical condition and is breathing through a tube.' 'His name is Cleiton,' she adds. 'He's eight years old.' Jesse Copelyn/GroundUp Many other children have already perished. A 20-minute drive from Tica is the settlement of Mutua, in the Dondo district. There, activist Carlota Francisco says, 'During this pause, we had cases [of children] that were really critical that ended up losing their lives.' One of them had been a 2-year-old girl under her care. 'That child depended on me,' says Francisco, who explains that she would fetch and provide the girl's ARVs. After she stopped, she says the girl's caregivers failed to give her the correct dosages. The 2-year-old died shortly thereafter. Stories such as this were repeated in almost every village that we visited. Often, children or their caregivers attempted to get the medication without the activists. But many of the hospitals were in a state of chaos because USAID-funded health workers and data capturers had been laid off. The linkage officers that knew these children and had previously assisted them were gone too. (The procurement of the country's ARVs is financed by The Global Fund to Fight AIDS, Tuberculosis and Malaria. This money continues to flow, but the distribution of these drugs to hospitals relies on US money.) Endless queues, drug shortages and the loss of patient files meant some didn't get their medication. Rates of ARV treatment fall throughout the province The director of health for the Buzi district, Roque Junior Gemo, explains that a key role of the community workers had been to extend health services to remote areas that they had long struggled to reach. 'They are like our tree branches to bring services to the people,' says Gemo, 'Our villages are very remote, and we have a large population that needs information [and] basic services.' 'Especially in the HIV area, we have terminal patients who were once followed up by activists. They used to get medications at home. Without that help, their condition worsened, and some died.' This forms part of an issue that extends far beyond the district of Buzi. In the Sofala capital of Beira, I sat down with some of the province's senior health officials. The HIV supervisor for the province, Manuel Seco, provided data on the HIV response in Sofala, before and after the cuts. Between May and December of 2024, the total number of people on ARVs in the province had risen by over 20 /000 people, the data shows. This increase occurred steadily, rising by 500 to 5 000 people each month. But as soon as the cuts were made, this progress was halted and the trend reversed. Since January, the number of people on ARV treatment has been falling by hundreds of people each month. The reason, according to Seco, is that many people who were on ARVs have stopped their treatment, while new ARV initiations have dropped sharply. And the impact extends far beyond just the HIV response. Jesse Copelyn/GroundUp TB left untreated Buried within a compound owned by Tongaat Hulett is a government hospital that services the rural population of Mafambisse, in Dondo district. Joaquim Mupanguiua, who deals with TB at the hospital, says that after the activists were laid off, the hospital saw a steep decline in the number of TB patients coming to the facility. 'Only when they are already very ill do they come to the health unit,' he says. 'But with the activists they would easily go to the communities and find the sick.' Indeed the number of patients coming to the hospital is roughly a third of what it once was: 'We used to get around 28 to 30 [TB] patients per month, but now we're down to fewer than 10,' Mupanguiua notes. Because patients come to the hospital when they're already severely ill, there's significantly less that health facilities can do for them. It's thus no surprise that Mupanguiua believes that there has been an uptick in needless TB deaths. Finding other ways Back in the Buzi district office, Gemo says that efforts have been made to assist terminal patients that had previously been supported by activists, but there are so many people in need that they aren't able to help everyone. Activists often said something similar – they continue to visit their beneficiaries when they can, they say, but without ComuSanas sponsoring their transport costs, many struggle to visit children in remote areas. And the loss of their income with the programme means that they now need to spend their days finding other ways to survive – subsistence farming and street markets are the usual routes. But this work rarely offers the kind of regular income that ComuSanas had been providing. 'Honestly, buying notebooks, pens and clothes for my children [has become] very difficult,' says Dondo-based activist, Brito Balao. Meanwhile, in Tica, activists asked how they could provide food to their former beneficiaries when they are themselves going hungry. Despite this, the activists still live within the same villages as their beneficiaries. And so unlike those in Washington, they cannot withdraw their support without facing the resentment or desperation of their communities. 'We work with love, and we get really sad not being able to be there for those kids,' says one Mutua-based activist. 'There's even another family that cried today [when they saw me]. 'You've been away for a while,' they said. Gosh, we feel bad.' Among former beneficiaries of the programme the sense of abandonment was palpable, and their anger was often directed at the former activists. This was often compounded by the fact that no one had explained to them why the programme had stopped. Jesse Copelyn/GroundUp In the village of Nharuchonga, Joana, explains that in the past her activist, Fatima, would always come and ensure that her daughter took her ARVs. Now that Fatima has stopped coming, her daughter doesn't always take the medication, she says. (Fatima is present during this conversation.) 'We've been abandoned by Fatima,' she states, looking directly away from the former activist. 'Until now we have been too shy to ask why she has abandoned us.' In many other cases, the tone was simply one of sadness. Back in Tica, inside an outdoor kitchen made of corrugated iron sheets, Maria holds her five-year-old granddaughter Teresa. Despite facing hunger at various points over recent years, she cooks sweet potatoes above a small fire, and insists that everyone eats. Both of Teresa's parents died of AIDS, says Maria. It has been left to her to raise the child, all the while trying to grow rice and maize for subsistence – an effort hampered by frequent drought. For a long time Maria has had help with this parental role, she says. Activist Marta Jofulande had been assisting her family and acting like a mother to the child. But since the programme was terminated, they don't see much of Jofulande anymore. Instead, five-year-old Teresa has been forced to deal with the exit of yet another parental figure./ A note on quotes: Most of our interviews were in Portuguese and were mediated by a local translator. We subsequently transcribed and translated the recordings of these interviews using AI-based software, including Descript and ChatGPT. Where there was a significant mismatch between the interpretations of the translator and the software, we contacted the interviewee or got third parties to help translate the recordings. The cost of travel, accommodation and the journalist's remuneration was shared between GroundUp and Spotlight.
News.com.au
an hour ago
- Business
- News.com.au
Scott Power: ASX health stocks fall in ‘lacklustre week'
ASX heath sector falls 1.1% over past five days The US FDA approves CSL's Andembry to prevent attacks of hereditary angioedema Clever Culture systems records its second consecutive quarter of positive cashflow operations Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. The ASX healthcare sector has had what Morgans' senior healthcare analyst Scott Power described as a "lacklustre week". At lunchtime on Friday, the S&P/ASX 200 Health Care index (ASX:XHJ) was down 1.1% for the past five days, while the benchmark S&P/ASX 200 (ASX:XJO) fell 0.55% for the same period. Markets have been influenced by global economic and geopolitical concerns, particularly escalating tensions between Iran and Israel. And it seems US President Donald Trump has not backed down from tariffs on pharmaceutical imports. A United States Department of Commerce investigation is underway under Section 232 of the Trade Expansion Act of 1962 – a provision that allows the president to restrict imports if they are deemed a threat to national security. Returning from the G7 Summit in Canada Trump reportedly told media on Air Force One tariffs on the sector were coming. "We're going to be doing pharmaceuticals very soon," he said. "That's going to bring all the companies back into America... at least partially back in." Power said Trump's latest comments were adding further jitters to the sector. "Until we get clarity there's going to be volatility," he said. Power's Powerplay – CSL gets FDA approval for Andembry The ASX's largest healthcare stock CSL (ASX:CSL) has notched a milestone with the FDA approving its Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE). Affecting about one in 50,000 people CSL said HAE was the first and only treatment targeting factor XIIa for prophylactic use to provide sustained protection from attacks of HAE in adult and pediatric patients aged 12 years and older. The approval was based on a pivotal phase III (VANGUARD) trial and ongoing open-label extension study, showing Andembry reduced the median number of HAE attacks by more than 99% (mean 89.2%), compared to placebo. Andembry is also the only treatment to offer once-monthly dosing from the start for all patients and is administered via an autoinjector. The drug is already available in Australia, the UK, EU, Japan, Switzerland and UAE. CSL said Andembry will be launched "immediately", with availability through third-party specialty pharmacy network before the end of June. In a note to clients, Morgans' healthcare analyst Derek Jellinek wrote that while Andembry's US approval had taken longer than expected, with application filing in December '24, it's good to see the drug greenlit before the end of '25 "despite the ongoing tumultuous environment" at the US Food and Drug Administration at the agency. "We view Andembry's unique MOA (ie upstream inhibition of key pathways leading to HAE attacks, so broader applicability), favourable safety profile and convenient dosing (every 4 weeks via subcutaneous injection) as key differentiators," Jellinek wrote. While Andembry is expected to impact Berinert sales – CSL's treatment for acute HAE attacks – Jellinek believes the effect should be modest. He wrote Berinert's revenue was forecast to remain steady in FY25 at US$242 million, accounting for less than 2% of CSL's total revenue. Sales are projected to ease slightly to US$230m in FY26 and US$225 million in FY27. However, this is more than compensated by anticipated growth in Andembry sales, which are expected to reach US$120m in FY26 and increase to US$220m in FY27. Morgans has an add rating on CSL and 12-month target price of $329.26. Clever Culture Systems delivers clever Q3 FY25 result Clever Culture Systems (ASX:CC5) has achieved its second consecutive quarter of positive cashflow operations with $500,000 net cash inflow in Q3 FY25 and is on track to achieve break-even or better for H2 FY25. During the quarter Clever Culture continued to execute on its commercialisation strategy for its APAS Independence instruments in the pharmaceutical market, building on success with big pharma companies Astra Zeneca and Bristol Myers Squibb (BMS). The instruments use artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. Since launching the product in March 2024, Clever Culture said it had completed sales and received orders from pharmaceutical customers for 13 APAS instruments, representing ~$6 million in revenue with a pipeline of 40 qualified opportunities. Clever Culture finished Q3 FY25 with a cash position of $2.2m. "Other top 10 pharmaceutical companies are expected to engage with CC5 following the AstraZeneca and Bristol Myers Squibb success," Power said. Emvision awarded $5 million government grant EMVision Medical Devices (ASX:EMV) has been awarded a $5 million federal government grant to further development of its First Responder portable brain scanner. The funds are by way of an Australian government Industry Growth Program (IGP) Commercialisation and Growth Grant. First Responder is EMVision's second product and distinguishes between bleed and clot strokes at the scene and is designed to be used by ambulances and by paramedics. The device should shorten diagnosis time, a crucial element in the patient getting the right treatment. EMVision's first commercial device – the emu bedside brain scanner – is also designed to rapidly diagnose stroke at the point-of-care with a pivotal trial underway to supports US Food and Drug Administration (FDA) de novo (new device) clearance. Audeara hits record, Micro-X gets milestone payment boost In other news of the week, specialist in listening solutions for people with hearing challenges Audeara (ASX:AUA) has delivered record revenue exceeding $3.64 million for the 11 months to end of May FY25. Audeara reported revenue for the 11-month period was up 14% on FY24 total revenue and 25% on FY23, which the company said signalled underlying strength of its ongoing operations. The company expects additional growth to materialise in coming weeks based on strong June 2025 trading. And leader in cold cathode x-ray technology for health and security markets Micro-X (ASX:MX1) has received $2.3 million in milestone payments for two projects. MicroX achieved milestone three under its development agreement with US Advanced Research Projects Agency for Health (ARPA-H) and Department of Homeland Security (DHS) for a full body CT scanner, delivering $1.4 million. The company also achieved milestone two under a strategic partnership deal with Billion Prima for a baggage and parcel scanning unit due for completion in 2025, delivering $900,000. "We are pleased to continue to deliver strong progress on these key development contracts with ARPA-H, DHS, and Billion Prima respectively, which is a testament to our focus and timely delivery on key projects," Micro-X CEO Kingsley Hall said. "We are also well advanced with the final stages of our Head CT development as we prepare to enter human imaging trials." The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While Clever Culture Systems, Audeara and EMVision are Stockhead advertisers, the companies did not sponsor this article.
ABC News
an hour ago
- Health
- ABC News
South Australian government to allow GPs to diagnose ADHD
Some general practitioners in South Australia will from next year be able to diagnose patients with attention deficit hyperactivity disorder (ADHD), in a move the state government says will cut wait times and costs for those seeking a diagnosis. Currently, adults in South Australia seeking an ADHD diagnosis must be assessed by a psychiatrist, while children must see a paediatrician. The state government argues the existing regulations have made it "extremely difficult" to get an ADHD diagnosis due to long wait times and high costs to see a specialist. Rule changes announced by the government on Friday will allow specially trained GPs to diagnose the disorder. It will also allow GPs to prescribe ADHD medication without having to provide evidence to SA Health of a diagnosis from a psychiatrist or paediatrician. The reforms will come into effect in 2026. Health Minister Chris Picton said some patients have spent more than $2,000 for a diagnosis. "That's a huge expense for South Australians and it means that people are missing out on important healthcare that can make a difference for them," he said. Mr Picton also argued the reforms would free up "significant capacity" for psychiatrists and paediatricians to undertake other mental health work. "We know that there's significant need in the community for a whole range of other afflictions people have," he said. The reforms follow a similar move by New South Wales earlier this year. The Western Australian government has also committed to the reform. Specialist training for GPs who want to be involved in ADHD diagnoses will be made available from next year. This is on top of online training modules that are already available through the Royal Australian College of General Practitioners (RACGP). RACGP chair Siân Goodson said not all GPs will take up the additional training. But she added that many GPs already have experience dealing with ADHD patients. "GPs are often co-managing these patients already, so we often prescribe once we've got the diagnosis is confirmed," she said. "So, we're already getting experience in managing medication and managing these people." Dr Goodson, who is also a GP in Adelaide's northern suburbs, said patients are regularly reporting ADHD symptoms to their doctor. She said early ADHD diagnosis was "really important" for children. "We see people waiting a long time for that diagnosis falling behind at school and the outcomes are less good," she said. "But also for adults, sometimes they've struggled for a long time, they've lost their job or they're not functioning at home. Mother Vaia Allen said she spent around $3,000 on getting an ADHD diagnosis for her 12-year-old daughter Pippa. The cost, Ms Allen said, did not include ongoing medication and regular GP appointments. She also needed to travel from Victoria to South Australia. Ms Allen said her daughter has been on ADHD medication for around four months and it has greatly helped her learning in school. "When we got Pip on ADHD medication, it was so helpful … in her classroom for her teacher, the students around her, and obviously for herself," she said. "It's really obvious to me that the education outcomes are so important in terms of their focus and changing their life trajectory. "She can sit there, listen and understand now." Deborah McLean, president of the South Australian Psychologists Association (SAPA), welcomed the state government's rule changes. She also expressed confidence that the training offered to GPs will be sufficient to correctly diagnose ADHD. But she cautioned that some ADHD patients will still need access to "holistic diagnosis assessment and then treatment" for concurrent conditions like depression and anxiety. "It means that we may only be treating part of the problem. "I think for a lot of people, though, this is a really positive step forward and a way to be able to access the essential services they need." The Royal Australian and New Zealand College of Psychiatrists (RANZCP) SA Branch also welcomed the rule changes. But the college cautioned that the government "must prioritise patient safety and quality outcomes through greater training and support for doctors treating ADHD". RANZCP SA chair Patrick Clarke, a North Adelaide psychiatrist, said he currently treats around 150 ADHD patients. "That's all I can manage, and I can't take on any more," Dr Clarke said in a statement. "So, we're glad to see the SA government doing more to expand access to ADHD care in the state for people who are missing out on help. "Giving trainee specialists more ADHD exposure will greatly increase the pool of doctors with appropriate exposure to see these patients."
Yahoo
an hour ago
- Climate
- Yahoo
UK weather - live: Heatwave conditions intensify as Met Office forecasts temperatures of 33C
Temperatures of up to 33C are expected on Friday amid warnings the UK could break its record for the hottest day of the year for the second day in a row,. An amber heat-health alert for all regions is in force until Monday - the first of its kind since September 2023. It warns 'significant impacts are likely' across health and social care services, including a rise in deaths, particularly among those aged 65 and over or people with health conditions. After sweltering temperatures in recent days, a number of areas are expected to have passed the official heatwave criteria by Friday afternoon, the Met Office has said. Temperatures reached as high as 32.2C in Kew, west London, on Thursday and are expected to hit the low 30s again today. Follow our live coverage of the heatwave conditions below: The UK could break its record for the warmest day of the year for the second day in a row, with temperatures up to 33C forecast. Temperatures will be in the low 30s, and probably be the peak of the hot spell on Saturday, as 34C is possible, still below the June record of 35.6C in 1976. Sunday will be another very warm day in the south and east probably in the late 20s, elsewhere it will be cooler, with temperatures in the mid 20s, Mr Stroud said. Read more from PA The UK could break its record for the warmest day of the year for the second day in a row, with temperatures up to 33C forecast. Temperatures will be in the low 30s, and probably be the peak of the hot spell on Saturday, as 34C is possible, still below the June record of 35.6C in 1976. Sunday will be another very warm day in the south and east probably in the late 20s, elsewhere it will be cooler, with temperatures in the mid 20s, Mr Stroud said. Read more from PA
